Tuesday, August 27, 2019 6:17:26 PM
Braunwald’s Heart Disease Welcomes Two New Editors
8/27/19
Paris, August 31, 2019 – Elsevier, a global information analytics business specializing in science and health, is pleased to welcome Deepak L. Bhatt, M.D., M.P.H., and Scott D. Solomon, M.D., to the prestigious Braunwald’s Heart Disease Editorial team, as planning for the 12th edition begins.
Trusted by generations of cardiologists for the latest, most reliable guidance in the field, Braunwald’s Heart Disease continues to be one of the leading sources of information on rapidly changing clinical science, clinical and translational research, and evidence-based medicine.
The editors salute Dr. Douglas Zipes who contributed to Braunwald’s Heart Disease since the second edition and served as editor-in-chief for two editions. His energy, expertise and experience contributed enormously to the success of this book and its companions. As Prof. Zipes leaves the editorial group to pursue other interests, Dr. Gordon Tomaselli now leads the electrophysiology and arrhythmia sections of Heart Disease.
Drs. Bhatt and Solomon will join Braunwald’s Heart Disease as new co-editors for the 12th Edition. They both have made major contributions to contemporary cardiovascular medicine, and each has several areas of expertise that they bring to the editorial team.
“We are fortunate to have such talented, accomplished and experienced clinician-investigators and teachers join us. Their contributions will help us continue the tradition of excellence established by Dr. Braunwald and assure the high quality of the 12th edition and its usefulness to practitioners and trainees for learning and as the cardiovascular reference for their practices,” said Prof. Peter Libby, who will take the role as lead editor of the 12th edition.
Dr. Bhatt, Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart & Vascular Center, and Professor of Medicine, Harvard Medical School, has authored over 1250 publications and is the editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease.
“What an incredible honor and joy it is to be joining this all-star team of Braunwald’s Heart Disease Editors,” Dr. Bhatt said.
Dr. Solomon is The Edward D. Frohlich Distinguished Chair, Professor of Medicine at Harvard Medical School and Senior Physician at Brigham and Women’s Hospital. Dr. Solomon has authored more than 600 peer-reviewed articles, reviews and editorials, three textbooks of cardiac imaging, including Essential Echocardiography, A Companion to Braunwald’s Heart Disease (2018), and the Echocardiography sections for the 10th and 11th edition of Braunwald’s Heart Disease.
“It is a distinct honor to join this extraordinary team on what is arguably the premiere educational source in cardiovascular medicine,” said Dr. Solomon.
Editors of Braunwald’s Heart Disease, 12th edition, also include:
Peter Libby, M.D., Senior Physician, Brigham and Women’s Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School;
Robert Bonow, M.D., Max and Lilly Goldberg Distinguished Professor of Cardiology, Northwestern University Feinberg School of Medicine;
Douglas L. Mann, M.D., Chief, Cardiovascular Division, Lewin Chair and Professor of Medicine, Washington University School of Medicine, Cardiologist-in-Chief, Barnes Jewish Hospital;
Gordon F. Tomaselli, M.D., The Marilyn & Stanley M. Katz Dean, The Albert Einstein College of Medicine, Executive Vice President and Chief Academic Officer, Montefiore Medicine.
Braunwald’s Heart Disease, 11th edition, is available to purchase in both single volume and two-volume formats. The print copy of the book includes the enhanced digital version e-book, also available via elsevierhealth.com for purchase by itself, and at industry events and conferences, including ESC 2019.
About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
Recent AMRN News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM